Quantbot Technologies LP reduced its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 26.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,450 shares of the company's stock after selling 29,868 shares during the period. Quantbot Technologies LP's holdings in Cellebrite DI were worth $1,860,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in shares of Cellebrite DI by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company's stock worth $7,202,000 after purchasing an additional 75,092 shares during the last quarter. Two Sigma Advisers LP raised its stake in Cellebrite DI by 9.8% during the third quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company's stock valued at $22,584,000 after buying an additional 120,000 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in Cellebrite DI by 65.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company's stock worth $3,473,000 after buying an additional 62,320 shares during the last quarter. State Street Corp grew its position in shares of Cellebrite DI by 7.3% in the 3rd quarter. State Street Corp now owns 443,700 shares of the company's stock worth $7,472,000 after acquiring an additional 30,052 shares in the last quarter. Finally, New York State Common Retirement Fund increased its holdings in shares of Cellebrite DI by 2.6% in the 4th quarter. New York State Common Retirement Fund now owns 189,599 shares of the company's stock valued at $4,177,000 after acquiring an additional 4,838 shares during the last quarter. Institutional investors own 45.88% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on CLBT. JPMorgan Chase & Co. raised their price objective on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Lake Street Capital lifted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a research note on Thursday. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $23.43.
Read Our Latest Stock Analysis on Cellebrite DI
Cellebrite DI Stock Down 1.7 %
Cellebrite DI stock traded down $0.34 during mid-day trading on Thursday, hitting $19.61. 919,423 shares of the company's stock traded hands, compared to its average volume of 1,124,376. Cellebrite DI Ltd. has a one year low of $10.25 and a one year high of $26.30. The company has a market cap of $4.70 billion, a PE ratio of -14.11, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52. The firm has a 50 day moving average price of $20.98 and a 200 day moving average price of $19.85.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
